Esperion Therapeutics. has been granted a patent for methods to prepare and purify 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. The patent also covers compositions and pharmaceutical materials containing this compound, along with methods for treating various diseases and conditions using these formulations. GlobalData’s report on Esperion Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Esperion Therapeutics, NSAID cancer drugs was a key innovation area identified from patents. Esperion Therapeutics's grant share as of June 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
The patent US11987548B2 outlines a method for preparing a pharmaceutical material that includes a compound represented by formula (V). The process involves several steps, starting with the formation of an intermediate compound using a specific molar ratio of ethyl isobutyrate to a substituted 5-chloropentane. The method specifies that less than 1% by weight of the substituted 5-chloropentane should remain after this initial step. Subsequent steps include the use of sodium iodide as a salt, and a defined molar ratio of another compound to toluenesulfonylmethyl isocyanide. The method also details the use of a reducing agent in a controlled manner to yield a second intermediate, which is then hydrolyzed to produce the final compound of formula (V).
Further refining the process, the patent describes purification steps that ensure the pharmaceutical material contains a high purity of the compound of formula (V), exceeding 99% by weight. This purification can involve crystallization from solvents such as ethyl acetate and water, with specific temperature ranges for both crystallization and recrystallization processes. Additional steps include adjusting the pH of the solution, extracting the compound using methyl tert-butyl ether, and filtering through silica gel. The method also allows for further purification through charcoal treatment, culminating in a final crystallization step to achieve the desired pharmaceutical material. The claims emphasize the precision in ratios and conditions necessary for effective synthesis and purification of the compound, which is critical for pharmaceutical applications.
To know more about GlobalData’s detailed insights on Esperion Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
